With $185 million in series A funding and an army of experienced leaders in its ranks, Braveheart Bio is setting off to joust with big names in an emerging heart disease drug arena. Backed by ...

A new West Coast biotech has emerged into the busy in vivo cell therapy space, this time with the backing of Nobel Prize-winning CRISPR pioneer Jennifer Doudna, Ph.D. Azalea Therapeutics has bloomed ...

Cathy Tie left university to found her first biotechnology company at the age of 18. In the 11 years since, she has launched several more. Her first company helped genetic-testing firms to interpret ...

In September 2024, Akeso, a little-known Chinese biopharmaceutical company, announced that clinical trials had shown that its new drug could halt the progression of a type of lung cancer for nearly a ...

On a Friday in August, Dominique Verhelle was laid off over Zoom. Three days later, on a Monday, she realized it was the first time in her life without a job. “It’s my baby,” Verhelle said of NextRNA ...

A hand holds up a tamper-safe orange bottle filled with oblong white pills against a red-tinted background of Chinese yuan. As China’s biopharmaceutical industry churns out more innovative molecules, ...

Mr. Dreyer is an American editor and writer who lives in Shanghai. Just outside Shanghai, in the city of Wuxi, China is building its future of medicine — a booming biotechnology hub of factories and ...

Marianne De Backer, PhD, MBA, CEO of Vir Biotechnology, has led the company's pivot to focusing on cancer as well as infectious diseases. [Vir Biotechnology] Between launching clinical studies for its ...

Just north of San Francisco International Airport lies one of the densest clusters of biotechnology companies in the world. The neighborhoods along Brisbane’s and South San Francisco’s eastern ...

Allison DeAngelis is the East Coast biotech and venture capital reporter at STAT, reporting where scientific ideas and money meet. She is also co-host of the weekly biotech podcast, The Readout Loud.